For the year ending 2025-12-31, SLS had $57,907K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -26,863 |
| Non-cash stock-based compensation | 1,956 |
| Non-cash lease expense | 597 |
| Prepaid expenses and other assets | 968 |
| Accounts payable | -535 |
| Accrued expenses and other current liabilities | -1,941 |
| Operating lease liabilities | -635 |
| Net cash used in operating activities | -28,389 |
| Proceeds from warrant inducements, net of issuance costs | 51,042 |
| Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs | 23,051 |
| Proceeds from the exercise of common stock warrants and pre-funded warrants | 12,618 |
| Proceeds from employee stock plan purchases | 112 |
| Tax withholding on vesting of restricted stock units | 527 |
| Net cash provided by financing activities | 86,296 |
| Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents | 57,907 |
| Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of year | 13,986 |
| Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of year | 71,893 |
SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group, Inc. (SLS)